Mankind Pharma logo

Mankind Pharma financials and balance sheet

NSE: MANKINDBSE: 543904Pharmaceuticals & BiotechnologyMid Cap

Last close ₹2,212.60down ₹63.00 (2.77%)BSE ₹2,217.00

Share price at the NSE close on 23 Oct 2026. Previous close ₹2,275.60.

52-week range of traded prices to 23 Oct 2026
₹1,909.70Low, 23 Mar 2026₹2,642.00High, 29 Jul 2026
Market cap
₹91,390 Cr119th largest listed
P/E
44.6
P/B
5.6
Dividend yield
Nonein the last 12 months
ROE
13.4%
ROCE
12.8%
Debt to equity
0.38
Volume, NSE
6,79,10661.7% delivered

4 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Mankind Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹14,278 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue14,278
  2. Materials and goods−4,052
  3. Employee costs−3,184
  4. Other expenses−3,424
  5. Operating profit3,617
  6. Depreciation−886
  7. Other income+359
  8. One-off items−130
  9. Finance costs−639
  10. Profit before tax2,321
  11. Tax−395
  12. Joint ventures+12
  13. Net profit1,938

What the company owns

  • Plant, investments and other assets₹22,185 Cr
  • Inventory₹2,144 Cr
  • Receivables₹1,730 Cr
  • Current investments₹1,537 Cr
  • Cash and bank₹483 Cr

What pays for it: net worth and liabilities

  • Net worth₹16,561 Cr
  • Borrowings₹6,312 Cr
  • Other liabilities₹3,866 Cr
  • Owed to suppliers₹1,341 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Mankind Pharma quarterly results

₹ croreMar 2023Filed 30 MayMar 2024Filed 17 MayMar 2025Filed 25 JunMar 2026Filed 19 May
Revenue from operations8,74910,33512,20714,278
6,8497,8009,19010,660
Materials and goods bought2,9143,2103,4894,052
Employee costs1,9182,2752,6923,184
Other expenses2,0172,3153,0083,424
Operating profit before depreciation1,9012,5353,0183,617
Operating margin21.7%24.5%24.7%25.3%
Materials, % of revenue33.3%31.1%28.6%28.4%
Employee costs, % of revenue21.9%22.0%22.1%22.3%
Other expenses, % of revenue23.0%22.4%24.6%24.0%
Depreciation and amortisation326398621886
Operating profit after depreciation1,5752,1372,3972,731
Other income129281537359
Finance costs4434429639
Profit before one-off items and tax1,6592,3842,5042,451
One-off items000−130
Profit before tax1,6592,3842,5042,321
362458510395
Share of profit of joint ventures and associates12151212
Profit from discontinued businesses––5–
1,3101,9422,0111,938
Other comprehensive income−2−8−857
Total comprehensive income1,3081,9342,0031,995
Net margin15.0%18.8%16.5%13.6%
Net margin without joint ventures and associates14.8%18.6%16.4%13.5%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2023Filed 30 MayMar 2024Filed 17 MayMar 2025Filed 25 JunMar 2026Filed 19 May
7,6239,57614,56816,561
7,4359,36314,33216,300
Share capital40404141
Reserves7,3959,32314,29116,259
Belonging to outside owners of subsidiaries188213236261
1702078,5116,312
1,8632,1205,6646,507
2292687,5285,011
9,71511,96327,76028,080
5,2855,31320,58220,937
4,4276,6487,1757,140
Net debt−1,358−3,2496,2664,291
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2023Filed 30 MayMar 2024Filed 17 MayMar 2025Filed 25 JunMar 2026Filed 19 May
1,8132,1522,4133,121
2,1362,6322,9803,714
16720−146105
Receivables−205−290−124−172
Inventories262−55−221−51
Payables−6597−146210
Other working capital175268344117
Tax paid−323−480−567−593
Capital spending789315461626
Free cash flow1,0241,8371,9532,495
−1,054−2,082−12,683−196
−740510,290−2,953
Dividends paid00041
Shares bought back0000
Shares issued002,96321
Net change in cash197621−28
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Mankind Pharma dividend history

₹ per shareMar 2023Filed 30 MayMar 2024Filed 17 MayMar 2025Filed 25 JunMar 2026Filed 19 May
Earnings per share₹32.00₹47.75₹49.28₹46.35
Diluted earnings per share₹32.00₹47.68₹49.19₹46.28
Dividend per share–––₹1.00
Book value per share₹185.61₹233.73₹347.37₹394.87
Dividend payout–––2.2%
Shareholder yield–0.0%−3.0%0.0%
Market cap at the year end (₹ crore)–92,1651,00,03782,800

Ratios

Consolidated, years to March.Mankind Pharma PE ratio and valuation

RatioMar 2023Filed 30 MayMar 2024Filed 17 MayMar 2025Filed 25 JunMar 2026Filed 19 May
Revenue growth–18.1%18.1%17.0%
Operating profit growth–33.4%19.0%19.9%
Net profit growth–48.3%3.6%−3.6%
Earnings per share growth–49.2%3.2%−5.9%
17.2%22.8%17.0%12.5%
–5.5 pts−5.8 pts−4.5 pts
From the net margin–4.5 pts−2.5 pts−3.2 pts
From asset turnover–1.3 pts−7.2 pts−2.3 pts
From borrowing–−0.3 pts3.9 pts1.0 pts
Return on capital employed20.2%21.8%10.4%11.9%
Cash conversion138.5%110.8%120.0%161.0%
Interest cover35.463.75.64.3
Debt to equity0.020.020.580.38
Receivable days24304644
Inventory days188177219193
Payable days126125119121
Cash conversion cycle, days8581146117
Working capital days49446752
Asset turnover0.900.950.610.51
Assets per rupee of net worth1.311.291.681.82
Sales per rupee of plant3.473.534.204.82
Capital spending to depreciation2.420.790.740.71
Plant being built, % of plant in use19.5%7.1%10.5%22.1%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
6.9%
Cash from operations against operating profit
86.3%
Measure5 years3 years
Revenue growth, yearly rate–17.7%
Profit growth, yearly rate–14.3%
Return on equity, average17.4%17.4%
Return on capital employed, average16.1%14.7%
Operating margin, average24.1%24.9%
Net margin, average16.0%16.3%
Asset turnover, average0.750.69
Cash conversion cycle, days, average107115
Interest cover, average27.224.5
Debt to equity, average0.250.33

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore3 yearsLatest year
Cash from operations7,6873,121
Cash from investing−14,961−196
Cash from financing7,343−2,953
Capital spending1,402626
Dividends paid4141
Shares bought back00
Shares issued for cash2,98521
Borrowings raised16,8303,978
Borrowings repaid11,6586,218

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––45
Altman Z-scorePublished threshold 1.81–26.246.136.01
Beneish M-scorePublished threshold −1.78–−2.31−1.43−2.56
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–17.2661.83−3.53
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––1.211.30
Receivables growth less revenue growthOur threshold 0 percentage points–29.0463.23−4.53
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–−6.4926.07−13.71
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−0.344.15−0.37
Assets under construction, years of additionsOur threshold 2 years of additions–0.260.510.70
Effective tax ratePublished threshold 17.16 per cent21.8019.1920.3617.00
Tax charged less tax paid, % of profitOur threshold 10 percentage points2.32−0.92−2.28−8.54
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
12 May 2026ICRA Limited (opens in a new tab)Fund-based-Proposed limits[ICRA]AA+ /[ICRA]A1+Review, Re-affirmStable1,250
12 May 2026ICRA Limited (opens in a new tab)Non Convertible Debentures[ICRA]AA+Review, Re-affirmStable1,250
12 May 2026ICRA Limited (opens in a new tab)Commercial Paper[ICRA]A1+New, New600
22 Apr 2026CARE Ratings Limited (opens in a new tab)Fund-based/Non-fund-based-LT/STCARE AA+ / CARE A1+New, NewStable1,000
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.